
Orvirem
About Orvirem
Orvirem is a Healthcare company based in Russia, and was acquired by Alvogen in June 2015. Antiviral syrup for children against influenza and infections is manufactured. Its focus areas include Pharmaceutical Product Websites.
Company details
Orvirem is based in Russia within the pharmaceutical sector. Syrup-form antiviral medication is produced for children aged one year and older. Treatment and prevention of influenza along with other viral respiratory infections are targeted by this product. Medical professional guidance is required for its use, with potential side effects detailed in accompanying information. Resources on influenza and associated illnesses are supplied by the company. Operations focus on pediatric antiviral solutions.
- Headquarters Russia
- Stage Acquired
- SectorsHealthcare
- Website orvirem.ru
- Acquired by Alvogen (Jun 2015)
Investors in Orvirem
Orvirem has secured backing from 1 investor. Prominent investors backing the company include Alvogen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products are developed and marketed globally. | 2009 | alvogen.com | Montville, United States |
Investor details for Orvirem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Orvirem
Orvirem is headquartered in Russia.
Orvirem is based in Russia within the pharmaceutical sector. Syrup-form antiviral medication is produced for children aged one year and older. Treatment and prevention of influenza along with other viral respiratory infections are targeted by this product. Medical professional guidance is required for its use, with potential side effects detailed in accompanying information. Resources on influenza and associated illnesses are supplied by the company. Operations focus on pediatric antiviral solutions.
Orvirem has 1 investor. Key investors include Alvogen.
Yes. Orvirem was acquired by Alvogen in June 2015.